[Comparative analysis of the effectiveness of Botulinum toxin type A - hemagglutinin preparations of the Relatox and Botox complex in the treatment of patients with primary idiopathic blepharospasm].

OBJECTIVE

To analyze the effectiveness of Relatox (Botulinum toxin type A - hemagglutinin complex) in comparison with Botox in the treatment of primary idiopathic blepharospasm.

MATERIAL AND

METHODS

The study included clinical data for 21 patients with blepharospasm who were treated by botulinum therapy with Botox and Relatox for 3 years. The research method is a one-step retrospective analysis of medical data. Injections were carried out with a 3-month interval. On the 6th cycle, the drug was switched to Relatox. The clinical efficacy of the drugs was assessed using an 8-point Jankovich evaluation scale: the average values before the injection and 14 days after it were compared for each procedure.

RESULTS

Mean Jankovich scale scores decreased 2.5-fold for all cycles by the second week after the procedure (4.95 pre-injection vs. 1.8 post-injection), and the mean paired Student's T-criterion for all injections was 7.14 (with a critical value of 2.021 and a significance level of p=0.05). The mean paired Student's T-criterion for Botox was -6.63 and for Relatox -7.5 (with a critical value of 2.021 and a significance level of p=0.05), indicating a high efficacy of both drugs, slightly higher for Relatox.

CONCLUSION

A consistent trend of increasing efficacy with regular botulinum toxin injections and greater efficacy of Relatox compared to Botox in the treatment of patients with primary idiopathic blepharospasm has been demonstrated.